This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Cyclacel Pharmaceuticals 미래 성장
Future 기준 확인 5/6
Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 52.2% and 57.5% per annum respectively while EPS is expected to grow by 46.4% per annum.
주요 정보
52.2%
수익 성장률
46.4%
EPS 성장률
| Biotechs 수익 성장 | 30.6% |
| 매출 성장률 | 57.5% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 17 Jan 2024 |
최근 미래 성장 업데이트
업데이트 없음
Recent updates
수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 56 | 25 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -27 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -24 | N/A | N/A | 2 |
| 12/31/2023 | 0 | -23 | N/A | N/A | 3 |
| 9/30/2023 | 0 | -25 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -24 | -20 | -20 | N/A |
| 3/31/2023 | N/A | -23 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -21 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -19 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -19 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -20 | -22 | -22 | N/A |
| 12/31/2021 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2021 | N/A | -20 | -15 | -15 | N/A |
| 6/30/2021 | N/A | -18 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -15 | -9 | -9 | N/A |
| 12/31/2020 | N/A | -12 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -7 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | 0 | -8 | -10 | -10 | N/A |
| 6/30/2019 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2019 | 0 | -8 | -8 | -8 | N/A |
| 12/31/2018 | 0 | -7 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -14 | -7 | -7 | N/A |
| 3/31/2018 | N/A | -15 | -6 | -6 | N/A |
| 12/31/2017 | N/A | -15 | -7 | -7 | N/A |
| 9/30/2017 | 0 | -16 | -8 | -8 | N/A |
| 6/30/2017 | 0 | -10 | N/A | -10 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -11 | N/A |
| 12/31/2016 | 1 | -12 | N/A | -10 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 6/30/2016 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2016 | 2 | -13 | N/A | -13 | N/A |
| 12/31/2015 | 2 | -15 | N/A | -14 | N/A |
| 9/30/2015 | 2 | -16 | N/A | -15 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -18 | N/A |
| 3/31/2015 | 2 | -20 | N/A | -19 | N/A |
| 12/31/2014 | 2 | -20 | N/A | -19 | N/A |
| 9/30/2014 | 2 | -18 | N/A | -20 | N/A |
| 6/30/2014 | 1 | -19 | N/A | -16 | N/A |
| 3/31/2014 | 1 | -13 | N/A | -18 | N/A |
| 12/31/2013 | 1 | -20 | N/A | -18 | N/A |
| 9/30/2013 | 1 | -21 | N/A | -15 | N/A |
| 6/30/2013 | 1 | -18 | N/A | -15 | N/A |
| 3/31/2013 | 0 | -23 | N/A | -14 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: UXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
수익 vs 시장: UXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
고성장 수익: UXI is expected to become profitable in the next 3 years.
수익 대 시장: UXI's revenue (57.5% per year) is forecast to grow faster than the German market (5.4% per year).
고성장 수익: UXI's revenue (57.5% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if UXI's Return on Equity is forecast to be high in 3 years time